JP2020526575A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526575A5 JP2020526575A5 JP2020519196A JP2020519196A JP2020526575A5 JP 2020526575 A5 JP2020526575 A5 JP 2020526575A5 JP 2020519196 A JP2020519196 A JP 2020519196A JP 2020519196 A JP2020519196 A JP 2020519196A JP 2020526575 A5 JP2020526575 A5 JP 2020526575A5
- Authority
- JP
- Japan
- Prior art keywords
- migraine
- leucine
- pharmaceutical composition
- acceptable salt
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 133
- 229960000669 acetylleucine Drugs 0.000 claims description 69
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 claims description 68
- 206010027599 migraine Diseases 0.000 claims description 49
- 208000019695 Migraine disease Diseases 0.000 claims description 47
- 230000002265 prevention Effects 0.000 claims description 37
- 208000024891 symptom Diseases 0.000 claims description 19
- 239000002243 precursor Substances 0.000 claims description 13
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 claims description 10
- 206010019233 Headaches Diseases 0.000 claims description 10
- 231100000869 headache Toxicity 0.000 claims description 10
- 208000002173 dizziness Diseases 0.000 claims description 8
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- 206010028813 Nausea Diseases 0.000 claims description 6
- 208000026935 allergic disease Diseases 0.000 claims description 6
- 230000009610 hypersensitivity Effects 0.000 claims description 6
- 230000008693 nausea Effects 0.000 claims description 6
- 230000001720 vestibular Effects 0.000 claims description 5
- 206010003791 Aura Diseases 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 claims description 3
- 208000004998 Abdominal Pain Diseases 0.000 claims description 3
- 208000012639 Balance disease Diseases 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- 208000004044 Hypesthesia Diseases 0.000 claims description 3
- 208000016285 Movement disease Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 206010034972 Photosensitivity reaction Diseases 0.000 claims description 3
- 208000003443 Unconsciousness Diseases 0.000 claims description 3
- 206010047571 Visual impairment Diseases 0.000 claims description 3
- 208000034783 hypoesthesia Diseases 0.000 claims description 3
- 231100000862 numbness Toxicity 0.000 claims description 3
- 208000035824 paresthesia Diseases 0.000 claims description 3
- 230000036211 photosensitivity Effects 0.000 claims description 3
- 230000035900 sweating Effects 0.000 claims description 3
- 208000029257 vision disease Diseases 0.000 claims description 3
- 230000000007 visual effect Effects 0.000 claims description 3
- 230000004393 visual impairment Effects 0.000 claims description 3
- 206010050258 Basilar migraine Diseases 0.000 claims description 2
- 208000010541 Familial or sporadic hemiplegic migraine Diseases 0.000 claims description 2
- 206010019476 Hemiplegic migraine Diseases 0.000 claims description 2
- 208000000060 Migraine with aura Diseases 0.000 claims description 2
- 206010052784 Retinal migraine Diseases 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 claims description 2
- 208000017420 migraine with brainstem aura Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 206010016326 Feeling cold Diseases 0.000 claims 1
- 208000035238 familial hemiplegic 1 migraine Diseases 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 208000006122 sporadic hemiplegic migraine Diseases 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 65
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 65
- 239000003814 drug Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 10
- 238000000034 method Methods 0.000 description 7
- 230000035807 sensation Effects 0.000 description 4
- 208000037048 Prodromal Symptoms Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1709459.0A GB201709459D0 (en) | 2017-06-14 | 2017-06-14 | Treatment for migraine |
| PCT/IB2018/054676 WO2018229738A1 (en) | 2017-06-14 | 2018-06-25 | Treatment for migraine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526575A JP2020526575A (ja) | 2020-08-31 |
| JP2020526575A5 true JP2020526575A5 (https=) | 2021-08-12 |
| JP7130739B2 JP7130739B2 (ja) | 2022-09-05 |
Family
ID=59358204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020519196A Active JP7130739B2 (ja) | 2017-06-14 | 2018-06-25 | 片頭痛の治療 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11471434B2 (https=) |
| EP (1) | EP3638370B1 (https=) |
| JP (1) | JP7130739B2 (https=) |
| KR (1) | KR102594130B1 (https=) |
| CN (1) | CN111093772B (https=) |
| AU (1) | AU2018284330B2 (https=) |
| CY (1) | CY1123860T1 (https=) |
| DK (1) | DK3638370T3 (https=) |
| ES (1) | ES2847169T3 (https=) |
| GB (1) | GB201709459D0 (https=) |
| HR (1) | HRP20210108T1 (https=) |
| HU (1) | HUE053089T2 (https=) |
| IL (1) | IL271211B2 (https=) |
| LT (1) | LT3638370T (https=) |
| MA (1) | MA49396B1 (https=) |
| MD (1) | MD3638370T2 (https=) |
| MX (1) | MX387909B (https=) |
| PL (1) | PL3638370T3 (https=) |
| PT (1) | PT3638370T (https=) |
| RS (1) | RS61481B1 (https=) |
| SG (1) | SG11201912146RA (https=) |
| SI (1) | SI3638370T1 (https=) |
| SM (1) | SMT202100037T1 (https=) |
| WO (1) | WO2018229738A1 (https=) |
| ZA (1) | ZA201908087B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7337081B2 (ja) * | 2018-02-15 | 2023-09-01 | イントラバイオ リミティド | レストレスレッグズ症候群を治療するための治療薬 |
| JP7471298B2 (ja) * | 2018-12-06 | 2024-04-19 | イントラビオ エルティーディー | アセチル－ロイシンの重水素化類似体 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8701662L (sv) * | 1987-04-22 | 1988-10-23 | Gelder Nico M Van | Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna |
| US20040127501A1 (en) * | 2002-09-24 | 2004-07-01 | Zhengming Chen | Therapeutic agents useful for treating pain |
| US20060063827A1 (en) | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| MY142655A (en) * | 2003-06-12 | 2010-12-15 | Euro Celtique Sa | Therapeutic agents useful for treating pain |
| SI1641775T1 (sl) * | 2003-07-03 | 2009-08-31 | Euro Celtique Sa | 2-piridin alkinski derivati, uporabni za zdravljenje bolečine |
| SI1867644T1 (sl) * | 2003-07-24 | 2009-10-31 | Euro Celtique Sa | Heteroaril-tetrahidropiperidilne spojine, koristne za zdravljenje ali preprečevanje bolečine |
| EP1664041B1 (en) * | 2003-09-22 | 2008-07-02 | Euro-Celtique S.A. | Phenyl-carboxamide compounds useful for treating pain |
| PL1664016T3 (pl) * | 2003-09-22 | 2009-04-30 | Euro Celtique Sa | Środki terapeutyczne przydatne do leczenia bólu |
| ES2322907T3 (es) * | 2003-12-30 | 2009-07-01 | Euro-Celtique S.A. | Piperazinas utiles para el tratamiento de dolor. |
| FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| TN2010000251A1 (fr) | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| WO2011162409A1 (en) * | 2010-06-22 | 2011-12-29 | Shionogi & Co., Ltd. | Compounds having trpv1 antagonistic activity and uses thereof |
| SMT201600385T1 (it) | 2010-06-25 | 2017-03-08 | Shire Human Genetic Therapies | Trasporto di agenti terapeutici all’snc |
| MX340112B (es) * | 2010-11-09 | 2016-06-27 | Mannkind Corp | Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas. |
| US9394293B2 (en) * | 2011-08-10 | 2016-07-19 | Purdue Pharma L.P. | TRPV1 antagonists including dihydroxy substituent and uses thereof |
| US10905670B2 (en) | 2016-04-19 | 2021-02-02 | Intrabio Ltd. | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
| NZ750391A (en) | 2016-08-11 | 2026-03-27 | Intrabio Ltd | Pharmaceutical compositions and uses directed to lysosomal storage disorders |
| WO2018029658A1 (en) | 2016-08-11 | 2018-02-15 | Intrabio Limited | Therapeutic agents for neurodegenerative diseases |
| FI3600276T3 (fi) | 2017-03-28 | 2023-06-29 | Intrabio Ltd | Betahistiini tai sen farmaseuttisesti hyväksyttävä suola ja monoamiinioksidaasin inhibiittori käytettäväksi yhden tai useamman huimausoireen hoitamisessa tai ehkäisemisessä kohteessa |
| LT3697399T (lt) | 2017-10-18 | 2026-01-12 | Intrabio Ltd | Terapiniai agentai, skirti panaudoti gydant neramių kojų sindromą |
| US12458614B2 (en) | 2017-10-18 | 2025-11-04 | Intrabio Ltd | Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders |
| JP7337081B2 (ja) | 2018-02-15 | 2023-09-01 | イントラバイオ リミティド | レストレスレッグズ症候群を治療するための治療薬 |
| JP7471298B2 (ja) | 2018-12-06 | 2024-04-19 | イントラビオ エルティーディー | アセチル－ロイシンの重水素化類似体 |
| WO2020178721A1 (en) | 2019-03-02 | 2020-09-10 | Intrabio Ltd. | Leucine, acetyl leucine, and related analogs for treating disease |
| SI3989962T1 (sl) | 2019-06-28 | 2025-11-28 | Intrabio Ltd | Kombinirano zdravljenje z acetil-levcinom in miglustatom za zdravljenje lizosomske bolezni kopičenja |
| US20230051742A1 (en) | 2020-01-13 | 2023-02-16 | Intrabio Ltd. | Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers |
-
2017
- 2017-06-14 GB GBGB1709459.0A patent/GB201709459D0/en not_active Ceased
-
2018
- 2018-06-25 EP EP18749124.6A patent/EP3638370B1/en active Active
- 2018-06-25 HR HRP20210108TT patent/HRP20210108T1/hr unknown
- 2018-06-25 MA MA49396A patent/MA49396B1/fr unknown
- 2018-06-25 ES ES18749124T patent/ES2847169T3/es active Active
- 2018-06-25 LT LTEP18749124.6T patent/LT3638370T/lt unknown
- 2018-06-25 MD MDE20200433T patent/MD3638370T2/ro unknown
- 2018-06-25 PT PT187491246T patent/PT3638370T/pt unknown
- 2018-06-25 WO PCT/IB2018/054676 patent/WO2018229738A1/en not_active Ceased
- 2018-06-25 CN CN201880039532.2A patent/CN111093772B/zh active Active
- 2018-06-25 PL PL18749124T patent/PL3638370T3/pl unknown
- 2018-06-25 HU HUE18749124A patent/HUE053089T2/hu unknown
- 2018-06-25 SG SG11201912146RA patent/SG11201912146RA/en unknown
- 2018-06-25 US US16/622,785 patent/US11471434B2/en active Active
- 2018-06-25 RS RS20210046A patent/RS61481B1/sr unknown
- 2018-06-25 KR KR1020197038730A patent/KR102594130B1/ko active Active
- 2018-06-25 IL IL271211A patent/IL271211B2/en unknown
- 2018-06-25 AU AU2018284330A patent/AU2018284330B2/en active Active
- 2018-06-25 JP JP2020519196A patent/JP7130739B2/ja active Active
- 2018-06-25 SM SM20210037T patent/SMT202100037T1/it unknown
- 2018-06-25 DK DK18749124.6T patent/DK3638370T3/da active
- 2018-06-25 MX MX2019014784A patent/MX387909B/es unknown
- 2018-06-25 SI SI201830195T patent/SI3638370T1/sl unknown
-
2019
- 2019-12-05 ZA ZA2019/08087A patent/ZA201908087B/en unknown
-
2021
- 2021-01-18 CY CY20211100033T patent/CY1123860T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022153638A5 (https=) | ||
| JP2026035701A5 (https=) | ||
| JP7265990B2 (ja) | 神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 | |
| JP2023181322A (ja) | 睡眠時無呼吸を治療するための方法および組成物 | |
| IL315023A (en) | Neuroactive steroids for treatment of cns-related disorders | |
| JP2020516646A5 (https=) | ||
| JP2023073373A5 (https=) | ||
| JP2007182440A (ja) | アゴメラチンの、口腔粘膜または舌下投与のための口内分散性医薬組成物 | |
| US20140045801A1 (en) | Pramipexole transdermal delivery for severe headaches | |
| JP2019516756A5 (https=) | ||
| JP2021530543A5 (https=) | ||
| JP2020526575A5 (https=) | ||
| JP2016505050A5 (https=) | ||
| AU1774192A (en) | Composition and method containing optically pure (s) metoprolol | |
| CN101610760A (zh) | 恶病质的治疗 | |
| Moore et al. | Management of Motor | |
| Sweet et al. | Methyldopa as an adjunct to levodopa treatment of Parkinson's disease | |
| JP2021530568A5 (https=) | ||
| JP2015515971A5 (https=) | ||
| JP2020526575A (ja) | 片頭痛の治療 | |
| JPWO2021089678A5 (https=) | ||
| JPWO2022045336A5 (https=) | ||
| JPWO2020023324A5 (https=) | ||
| JPWO2021038500A5 (https=) | ||
| JP7034314B2 (ja) | うつ病を予防または治療するための安息香酸またはその塩および誘導体 |